Insight Guide

Small Molecule development – getting it right

Format: PDF file | Document type: Insight Guide | Promoted Content

This content is provided by Lonza Small Molecules, and any views and opinions expressed do not necessarily reflect those of

Small Molecule development – getting it right

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can be fraught with risk.

Increasing regulatory practice and the need for ever-evolving technologies means smaller companies need a supporting CDMO that matches the demanding requirements.

In our latest Q&A, Senior Director David Hall navigates the trends and risks in areas including technical challenges and regulatory compliance.

Download today for insights on how to achieve the best return from your next project.

Latest content from Lonza Small Molecules

show more

Lonza de-risks drug development through PBPK

Paid for and in partnership with Lonza Small Molecules

The opportunity to de-risk drug development through PBPK

No company wants to progress a molecule through to the clinic only to suffer a bad readout. PBPK modeling services allow companies to predict what absorption challenges may arise in trials, and plan ways to mitigate them.

Related resources from Lonza Small Molecules

Supplier info centre